Dianthus Therapeutics, Inc. (DNTH)
(Delayed Data from NSDQ)
$36.75 USD
-2.12 (-5.45%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $36.70 -0.05 (-0.14%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
DNTH 36.75 -2.12(-5.45%)
Will DNTH be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for DNTH based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for DNTH
Dianthus Therapeutics, Inc. (DNTH) Reports Q2 Loss, Lags Revenue Estimates
Earnings Preview: Dianthus Therapeutics, Inc. (DNTH) Q2 Earnings Expected to Decline
DNTH: What are Zacks experts saying now?
Zacks Private Portfolio Services
Seer, Inc. (SEER) Reports Q2 Loss, Beats Revenue Estimates
Dianthus Therapeutics, Inc. (DNTH) Reports Q1 Loss, Tops Revenue Estimates
Emergent Biosolutions (EBS) Q1 Earnings Top Estimates
Other News for DNTH
DNTH forms Slingshot Bullish on September 20
DNTH makes New 52 Week High on September 18
Is DNTH gaining bullish strength? New 52 Week Closing High shows up after advancing 3.76%
Clear Street Initiates Coverage on Dianthus Therapeutics (DNTH) with a 'Buy' Rating | DNTH ...
Fairmount Funds Management LLC Increases Stake in Dianthus Therapeutics Inc